Digital Health Global

MARCH 2, 2023

Koneksa’s digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.

Life Science 88

Life Science Drug Development BioTech Leadership 88

Digital Health Global

MARCH 16, 2023

Both Wellington and Forbion are visionaries and highly experienced biotech investors, and we look forward to working closely with them in our efforts to transform the gene editing landscape.” “Our billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development.

Life Science 88

Life Science Pharmaceuticals BioTech Drug Development 88

Digital Health Global

JUNE 20, 2023

These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,

BioTech 88

BioTech Life Science Leadership Drug Development 88